Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.


Our high-tech, dedicated method is applied to construct targeted libraries for receptors.


 

Fig. 1. The screening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.


Our library stands out due to several important features:


  • The Receptor.AI platform compiles comprehensive data on the target protein, encompassing previous experiments, literature, known ligands, structural details, and more, leading to a higher chance of selecting the most relevant compounds.

  • Advanced molecular simulations on the platform help pinpoint potential binding sites, making the compounds in our focused library ideal for finding allosteric inhibitors and targeting cryptic pockets.

  • Receptor.AI boasts over 50 tailor-made AI models, rigorously tested and proven in various drug discovery projects and research initiatives. They are crafted for efficacy, dependability, and precision, all of which are key in creating our focused libraries.

  • Beyond creating focused libraries, Receptor.AI offers comprehensive services and complete solutions throughout the preclinical drug discovery phase. Our success-based pricing model minimises risk and maximises the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
P48443

UPID:
RXRG_HUMAN

ALTERNATIVE NAMES:
Nuclear receptor subfamily 2 group B member 3; Retinoid X receptor gamma

ALTERNATIVE UPACC:
P48443; A6NIP1; Q6IBU7

BACKGROUND:
Retinoic acid receptor RXR-gamma, identified as Nuclear receptor subfamily 2 group B member 3, is crucial for retinoic acid signaling. It forms heterodimers with RAR to bind retinoic acid response elements (RARE), controlling gene expression that governs various biological functions, underscoring its importance in physiological and developmental pathways.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Retinoic acid receptor RXR-gamma unveils potential avenues for therapeutic intervention. Its central role in retinoic acid-mediated gene expression makes it an attractive target for developing novel treatments, emphasizing the importance of further research in this area.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.